S 3385 · 118th Congress · Government Operations and Politics
A bill to prohibit contracting with certain biotechnology providers.
Bill Progress
✓
Introduced2
Committee3
Senate Vote4
House5
EnactedLatest: Read twice and referred to the Committee on Homeland Security and Governmental Affairs.(2023-12-04)
Plain Language Summary
[AI summary unavailable — showing source text]
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions. Specifically, the bill prohibits executive agencies from (1) procuring, obtaining, extending, or renewing a contract to procure or obtain any biotechnology equipment or service produced or provided by a biotechnology company of concern; or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes. A biotechnology company of concern includes BGI Group, MGI Group, Complete Genomics, any subsidiary, parent affiliate, or successor of such entities, and any entity that is subject to the jurisdiction, direction, or control of a foreign adversary; operates primarily in the biotechnology industry; and the Department of Defense (DOD) deems to pose a risk to national security. DOD must determine, within 90 days after this bill's enactment, whether WuXi AppTec, Axbio, and any subsidiary, affiliate, or successor of such entities, or any other entity headquartered in or organized un…
Summarized by Claude AI · Non-partisan · For informational purposes only